熱門資訊> 正文
Ensys Biosciences收到纳斯达克的不合规通知
2024-09-28 04:57
- Ensysce Biosciences (NASDAQ:ENSC) said on Friday that it has received notice from the Nasdaq’s listing qualifications department stating that the company has not regained compliance with its listing rule, as the bid price for its common stock has remained below $1 per share.
- The company is not eligible for a second 180-day period because it does not comply with the minimum stockholders' equity requirement for initial listing on Nasdaq.
More on Ensysce Biosciences
- Ensysce Biosciences announces $5M concurrent offering, shares fall
- Ensysce wins $14M federal grant for lead pain therapy
- Seeking Alpha’s Quant Rating on Ensysce Biosciences
- Historical earnings data for Ensysce Biosciences
- Financial information for Ensysce Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
